EBITDA (Annual)

EBITDA: Income before interest, taxes, depreciation and amortization.

Regeneron Pharmaceuticals, Inc. (REGN) had EBITDA of $4.12B for the most recently reported fiscal year, ending 2025-12-31.

Quarterly Annual

Figures for fiscal year ending 2025-12-31

Income Statement Financials
Revenue	$14.34B
Net Income	$4.50B
Cost of Goods Sold	$2.10B
Gross Profit	$12.24B
Operating Expenses	$10.77B
Operating Income	$3.58B
Non-Operating Income/Expense	$1.65B
Pre-Tax Income	$5.23B
Normalized Pre-Tax Income	$5.23B
Income after Taxes	$4.50B
Income from Continuous Operations	$4.50B
Consolidated Net Income/Loss	$4.50B
Normalized Income after Taxes	$4.50B
EBIT	$3.58B
EBITDA	$4.12B
Weighted-Average Shares Outstanding (Basic)	104.60M
Weighted-Average Shares Outstanding (Diluted)	108.60M
Earnings per Share (EPS) (Basic)	$43.07
Earnings per Share (EPS) (Diluted)	$41.48
Balance Sheet Financials
Current Assets	$18.02B
Property, Plant, and Equipment	$5.12B
Long-Term Assets	$22.54B
Total Assets	$40.56B
Current Liabilities	$4.37B
Long-Term Debt	$2.71B
Long-Term Liabilities	$4.93B
Total Liabilities	$9.30B
Common Equity	$31.26B
Tangible Shareholders Equity	$30.00B
Shareholders Equity	$31.26B
Common Shares Outstanding	105.70M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$4.98B
Cash Flow from Investing Activities	$-629.10M
Cash Flow from Financial Activities	$-3.72B
Beginning Cash	$2.49B
End Cash	$3.12B
Increase/Decrease in Cash	$634.70M
Stock-Based Compensation	$993.70M
Common Stock Dividends Paid	$-370.30M
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	4.13
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.08
Debt to Equity Ratio	0.09
Gross Margin	85.35%
Operating Margin	24.95%
EBIT Margin	24.95%
EBITDA Margin	28.74%
Pre-Tax Profit Margin	36.47%
Profit Margin	31.41%
Free Cash Flow	$4.08B
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.35
Inventory Turnover	0.66
Receiveable Turnover	2.50
Days Sales in Receivables	146.10
Return on Equity	14.41%
Return on Tangible Equity	15.02%
Return on Assets	11.11%
Return on Investments	13.26%
Book Value Per Share	$295.71
Free Cash Flow per Share	$37.57
Operating Cash Flow per Share	$45.85

Data from Zacks Investment Research, Inc.